Antimicrobial resistance: what’s the issue, and why is it so important?

Antibiotic pills. Photo via Flickr

The Bureau has launched a new investigation into drug resistance in the UK, with the first story, Banned in America, soaring use in Britain: The poultry farm drugs that put human lives at risk, published today in the Independent.

What is the problem?

An estimated 700,000 people die each year around the world because they have an infection that has become immune to the drugs used to treat it. The UK Government’s review on drug resistance predicts that by 2050 this number will rise to 10 million deaths a year, with a cost to the global economy of $100 trillion.

What are antimicrobials?

An antimicrobial drug is used against a microorganism – like a bacteria, a virus, a parasite, or a fungus – which causes a disease.

There are different kinds of antimicrobial drug which work on the different organisms. Antibacterial drugs, or antibiotics, work against bacterial infections, and an antiviral works against a virus such as HIV.

What is antimicrobial resistance?

Resistance is a natural biological phenomenon. Some microorganisms naturally survive exposure to drugs which should kill them, and these surviving microorganisms pass on their resistance to the drug to others.

The first antibiotics were attack mechanisms that bacteria used to attack competitors. Resistance evolved as a defence against these chemicals. The same happens when humans administer synthesised antibacterial chemicals – the bacteria evolve resistance to the antibiotics.

But antimicrobial resistance can be accelerated by overuse or misuse of the drugs and poor infection control – like a visitor to a hospital transferring MRSA, a resistant infection, from one patient to another because they don’t wash their hands between patients.

Because resistant microorganisms are able to withstand attack by antimicrobial drugs, the usual treatments can become ineffective and infections last longer and can be more severe.

6813384933_1fb31d73fb_b
Scanning electromicrograph of an HIV-infected cell. Photo via Flickr

What is the situation in the UK?

Concerned about increasing antimicrobial resistance, the Government set up a five year antimicrobial resistance strategy in 2013. This sets out actions to slow the development and spread of antimicrobial resistance, with a focus on antibiotics.

Part of this strategy is the AMR Review. David Cameron asked economist Jim O’Neill to analyse the global problem of antimicrobial resistance and propose concrete actions to tackle it internationally. In 2014 the UK Government commissioned the AMR Review in collaboration with the Wellcome Trust.

The UK’s Chief Medical Officer also raised the alarm about the problem in 2013, saying antibiotic resistant is a “ticking time bomb” comparable to climate change and terrorism.

Antibiotics are used to treat infections like sepsis. More than 37,000 people die each year from sepsis in the UK – more than the number who die from lung cancer. Sepsis is a common condition caused by an infection which hospitalises 100,000 people a year in the UK.

Why is the Bureau covering antimicrobial resistance?

We will be looking at how antimicrobial resistance is rising in the UK, with a focus on antibiotics, and why that matters. By doing long term, public interest reporting on this subject, the Bureau will highlight the crisis of antimicrobial resistance and discuss solutions.

The first stage of our investigative work is focusing on antibiotics, food and farming – an under reported part of the problem.

Why is antibiotic resistance so important?

Because without effective antibiotics, infections – like sepsis, or food poisoning – can kill.

And as more and more bacteria become resistant to antibiotics, routine medical procedures which rely on antibiotics to prevent infection – like chemotherapy, organ transplants and hip replacements – will become impossible.

Antibiotics are not just used as a human medicine, but for diseases in animals as well. Around 45% of antibiotics used in the UK are given to animals – this includes food animals, like cattle, pigs and poultry, and pets such as dogs and cats.

How much information about antibiotic resistance is publicly available?

The Veterinary Medicines Directorate in the UK collects yearly data on antibiotic sales for veterinary purposes in the UK, but this is not broken down by antibiotic class or type of animal. Sales of antibiotics are also not wholly indicative of antibiotic use.

We have better data for human use of antibiotics, and as a result of this GP prescribing of antibiotics had decreased in recent years, following concerns about over-prescribing leading to antibiotic resistance.

8391004233_d84cb62720_o
Shigella bacteria. Photo via Flickr

What is the impact of antibiotic use on the problem?

Resistance develops when bacteria are exposed to the drugs, through a process of natural selection where the bacteria which are immune to the antibiotics are the ones that survive, and they then pass on the resistant genes. This process speeds up with repeated exposures.

The more humans use antibiotics and the more we give them to animals, the bigger the problem gets.

Critically important antimicrobials

The World Health Organisation has designated some antimicrobial drugs as “critically important”.

This is where the drug is the only, or one of the only, ways of treating a serious human disease, where the disease itself can be transmitted to humans from animals or where resistance of the disease to the drugs used to treat it can be transmitted to humans from animals.

The Bureau’s first story on antimicrobial resistance looked at the use of antibiotics called fluoroquinolones in poultry, and the potential impact that has on human health.

Fluoroquinolones are classed by the WHO as a critically important antibiotic.

Do you have a tip or story about antimicrobial resistance? Contact one of our reporters:

Andrew Wasley on [email protected] or
Victoria Parsons on [email protected]

Follow Victoria Parsons on Twitter. Read about the Drug resistance project here and join our mailing list here.

Comments